By Mauro Orru

Novartis's radioligand therapy, Lutathera, showed a significant improvement in survival for patients with gastroenteropancreatic neuroendocrine tumors.

Radioligand therapy is a form of precision nuclear medicine that Novartis is pursuing for cancer.

The Swiss pharmaceutical company said Monday that Lutathera had met its primary endpoint in a phase 3 trial, as treatment with Lutathera with long-acting octreotide showed a meaningful improvement in progression-free survival for patients with newly diagnosed somatostatin receptor-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors.

"These positive results for Lutathera are quite remarkable and they represent the potential for radioligand therapy to make a meaningful impact for newly diagnosed patients living with advanced GEP-NETs," said Jeff Legos, Executive Vice President for Global Head of Oncology Development at Novartis.

Novartis said it hadn't detected new or unexpected safety findings in the study.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

September 25, 2023 01:53 ET (05:53 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Nov 2023 até Dez 2023 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2022 até Dez 2023 Click aqui para mais gráficos Novartis.